Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07126873
PHASE1/PHASE2

A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes

Sponsor: EndoCell Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the safety, tolerability and efficacy of E-islet 01 in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia

Official title: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of E-islet 01 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2025-08-11

Completion Date

2029-12-31

Last Updated

2025-08-22

Healthy Volunteers

No

Interventions

BIOLOGICAL

Allogeneic Human E-islet (E-islet 01)

Allogeneic Human E-islet (E-islet 01), Infused into the hepatic portal vein

Locations (1)

Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, China